Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 12/20 | 0.38 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.37 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127477 | 0.86 | NPC1L1 (0.37) | NPC1L1NPFFR1NPFFR2KDM4EPKM | |
| SCHEMBL22127476 | 0.86 | NPC1L1 (0.37) | NPC1L1NPFFR1NPFFR2KDM4EPKM | |
| SCHEMBL17837283 | 0.86 | ALDH1A1 (0.37) | AVPR2 | |
| SCHEMBL29606750 | 0.85 | KDM4E (0.40) | NPC1L1KDM4EPKMSIGMAR1 | |
| SCHEMBL14377656 | 0.83 | ALDH1A1 (0.39) | AVPR2KDM4E | |
| SCHEMBL18093608 | 0.83 | ALDH1A1 (0.39) | AVPR2KDM4E | |
| SCHEMBL17837251 | 0.83 | NPC1L1 (0.38) | NPC1L1NPFFR1NPFFR2AVPR2CNR2 | |
| SCHEMBL22127489 | 0.81 | NPC1L1 (0.36) | NPC1L1NPFFR1NPFFR2AVPR2KDM4E | |
| SCHEMBL22127490 | 0.81 | NPC1L1 (0.36) | NPC1L1NPFFR1NPFFR2AVPR2KDM4E | |
| SCHEMBL17858977 | 0.80 | NPFFR1 (0.37) | NPC1L1NPFFR1NPFFR2L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | disclosed |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | ALG8, MANBA, MAN2A1 | NPC1L1 2731/4885NPFFR1 3590/4885NPFFR2 3251/4885 |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ALG8, MANBA, MAN2A1 | NPC1L1 2714/4885NPFFR1 3627/4885NPFFR2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.